✶ Written by an AI · fact-checked before publication
Every claim in Does Melatonin Actually Work?, checked
This is the book's verification ledger, published in full. Every factual claim was extracted from the manuscript and handed to an independent blind checker — one claim, its cited source, nothing else. High-stakes claims (doses, safety, real diseases, trial numbers) were checked by three checkers who had to agree. Every checker first had to confirm the cited source actually exists.
85claims checked
78verified first pass
7flagged & corrected
The honest part: 7 claims did not survive first contact with their own sources — the checkers flagged them as misstated or unsupported. Each one was corrected in the text and re-verified by a fresh blind panel before the book was published. The table below shows the first-pass verdicts, because that's the honest number: what the machine got wrong before checking, not after.
| id | claim as written | stakes | first-pass verdict |
|---|---|---|---|
| M1 | This book was written by "James Whitfield," an artificial intelligence (machine-written, stated on the cover). | — | verified |
| M2 | Every factual claim in the book was checked against its primary source, by machine, before publication. | — | verified |
| M3 | The machine-check caught the machine reaching past the evidence and cut or corrected the claim more than once in this book. | — | verified |
| M4 | A registered, practising Australian doctor reviewed the checked results and is accountable for what made the final page. | — | verified |
| M5 | Australian advertising rules bar a health practitioner from endorsing a therapeutic good in advertising. | — | verified |
| M6 | Australian rules restrict how a health practitioner's name and identity may be used in advertising of a regulated health service (the stated reason the reviewing doctor is unnamed) | — | misstated → corrected |
| M7 | Insufficient evidence to recommend" is a statement about the state of the evidence, not a finding that a treatment has been proven ineffective. | — | verified |
| M8 | Nobody involved in the book is the reader's doctor; the book has never met, examined, or seen the results of the reader and cannot diagnose them. | — | verified |
| M9 | The log of corrections to the book is published openly at jameswhitfieldauthor.com/corrections. | — | verified |
| M10 | No product, brand or treatment is endorsed anywhere in the book; nobody involved holds a commercial interest in any supplement; nothing is sponsored; and there | — | verified |
| M11 | In the United States melatonin is regulated and marketed as a dietary supplement, not as a drug. | — | verified |
| M12 | The US dietary-supplement framework does not require a manufacturer to demonstrate efficacy to the regulator before a product is sold. | — | verified |
| M13 | Consumer melatonin is sold in tablet, capsule, gummy, spray and liquid forms, at per-unit amounts commonly ranging from about 1 mg to 10 mg, with some products | — | verified |
| M14 | Books written specifically about melatonin argue in favour of its use, while the cautious reading exists only inside general sleep books and nowhere as a consumer audit of the aisl | — | unsupported → corrected |
| M15 | Melatonin is a hormone produced endogenously, principally by the pineal gland. | — | verified |
| M16 | Endogenous melatonin secretion is entrained to the light–dark cycle: it rises in darkness and is suppressed by light exposure. | — | verified |
| M17 | Melatonin was first isolated and identified in 1958. | — | verified |
| M18 | The human circadian system is entrained principally by light, with melatonin functioning as an output of that system as well as a feedback input to it. | — | unsupported → corrected |
| M19 | The benzodiazepines and the Z-drugs prescribed for sleep are modulators of the GABA-A receptor, and their sedation follows from their action at that receptor. | — | verified |
| M20 | Melatonin acts principally as a circadian timing signal (a chronobiotic) rather than as a hypnotic acting on the brain's arousal systems the way sedative-hypnot | — | verified |
| M21 | In a 1995 trial, amounts in the range of 0.1–0.3 mg were enough to reproduce the plasma melatonin concentrations of a normal physiological night — small relative to per-unit amount | — | misstated → corrected |
| M22 | The 2013 meta-analysis of melatonin for primary sleep disorders found a pooled reduction in sleep-onset latency of 7.06 minutes (95% CI 4.37–9.75) versus placeb | — | verified |
| M23 | The same 2013 meta-analysis found an increase in total sleep time of 8.25 minutes (95% CI 1.74–14.75) and a small improvement in sleep quality versus placebo. | — | verified |
| M24 | The AASM 2017 clinical practice guideline on pharmacologic treatment of chronic insomnia in adults did not recommend melatonin for sleep-onset or sleep-maintena | — | verified |
| M25 | The ACP 2016 guideline on management of chronic insomnia disorder in adults did not establish melatonin as a recommended treatment, finding insufficient evidenc | — | verified |
| M26 | Perceived benefit from a sleep aid can be inflated by expectancy effects and by regression to the mean after a run of poor nights. | — | verified |
| M27 | A 2024 dose–response meta-analysis found the sleep-promoting effect of exogenous melatonin increased with dose up to approximately 4 mg/day and plateaued therea | — | verified |
| M28 | Consumer melatonin products are commonly sold at 5 mg and 10 mg per unit — above the dose at which the pooled dose–response evidence stops showing additional be | — | verified |
| M29 | Melatonin does not carry the acute overdose profile or the dependence profile associated with sedative-hypnotic drugs. | — | verified |
| M30 | Melatonin is generally reported as well tolerated in short-term randomised controlled trials. | — | verified |
| M31 | The adverse effects most commonly reported in short-term melatonin trials include daytime sleepiness, headache, dizziness and nausea. | — | misstated → corrected |
| M32 | Data on the long-term safety of nightly melatonin use in healthy adults over years is limited. | — | verified |
| M33 | A 2025 observational analysis reported an association between long-term melatonin use and incident heart failure among adults with insomnia. | — | verified |
| M34 | That 2025 heart-failure finding was presented as a research abstract at a scientific meeting and has not been peer-reviewed or published as a full paper. | — | verified |
| M35 | Observational association cannot establish causation, and confounding by indication is a specific, well-recognised threat when the exposure studied is a treatme | — | verified |
| M36 | A Norwegian population study followed 54,279 adults for around eleven years and reported a higher rate of new heart failure in people carrying all three insomni | — | verified |
| M37 | Cohen et al. analysed 25 melatonin gummy products sold in the US and found 22 of 25 (88%) were inaccurately labelled for melatonin content, with measured conten | — | verified |
| M38 | That same 2023 JAMA gummy analysis detected serotonin in some of the specific products it tested (attributed to that assay and sample only — never generalised to melatonin products | — | misstated → corrected |
| M39 | An earlier analysis of melatonin supplements sold in Canada found melatonin content varied substantially from the labelled amount in the majority of products te | — | verified |
| M40 | In 2025 researchers analysed 110 melatonin products marketed for children using LC-MS/MS and reported substantial discrepancies between the labelled and measure | — | verified |
| M41 | In August 2025 the UK medicines regulator (MHRA) reported that undeclared melatonin had been found in children's magnesium glycinate gummy products sold through | — | verified |
| M42 | The same laboratory group assayed 57 sports supplements sold in the US: 23 of them (40%) contained no detectable amount of the labelled ingredient, those that d | — | verified |
| M43 | Under the US dietary-supplement regime, the melatonin content of a product is not verified against its label by a regulator before that product is sold. | — | verified |
| M44 | US poison control centre calls involving paediatric melatonin ingestions rose 530% between 2012 and 2021, with 260,435 such ingestions reported over that period | — | verified |
| M45 | Melatonin features prominently among the substances involved in US emergency-department visits for unsupervised paediatric medication exposures. | — | verified |
| M46 | A rise in poison-centre call volume is influenced by how widely a product is present in homes and cannot, on its own, establish a change in per-exposure risk. | — | verified |
| M47 | The large majority of reported paediatric melatonin ingestions were asymptomatic — 84.4% in the 2012–2021 surveillance. | — | verified |
| M48 | Over the 2012–2021 surveillance period the record includes 4,097 hospitalisations, 287 intensive-care admissions, 5 children requiring mechanical ventilation, a | — | verified |
| M49 | Trial evidence for melatonin in children is concentrated in specific clinical populations — notably children with autism spectrum disorder, ADHD and other neuro | — | verified |
| M50 | Long-term developmental safety data for routine nightly melatonin use in children is limited. | — | verified |
| M51 | Since 1 June 2021, modified-release melatonin at 2 mg or less has been a Schedule 3 (Pharmacist Only) medicine in Australia for monotherapy in the short-term tr | — | verified |
| M52 | Since 1 June 2023 a second Schedule 3 (Pharmacist Only) entry has applied to immediate-release melatonin of 5 mg or less for the treatment of jet lag in adults | — | verified |
| M53 | All other melatonin in Australia — every other strength, formulation and indication, and any product for anyone under 55 not treating jet lag — remains Schedule | — | verified |
| M54 | Melatonin is therefore not flatly prescription-only in Australia; the position is a split between two narrow pharmacist-only entries and prescription-only for e | — | verified |
| M55 | A Schedule 3 (Pharmacist Only) medicine in Australia can be supplied without a prescription but only by a pharmacist, following a pharmacist consultation. | — | verified |
| M56 | The TGA evaluates the quality, safety and efficacy of a prescription medicine before approving it for registration. | — | verified |
| M57 | Every batch of a medicine on the Australian Register must be certified as having been manufactured and controlled in accordance with its marketing authorisation | — | verified |
| M58 | Australians can lawfully import limited quantities of some medicines for personal use, and product that arrives that way has not been assessed by the TGA. | — | verified |
| M59 | Systematic review evidence supports melatonin for reducing jet-lag symptoms after travel across multiple time zones, with the effect most established for eastwa | — | verified |
| M60 | The sleep-disorders classification describes delayed sleep–wake phase disorder as habitual sleep and wake timing delayed relative to conventional timing — usual | — | verified |
| M61 | The DSWPD diagnostic criteria state that, allowed to keep their own schedule, these sleepers are expected to show improved sleep quality and duration for their | — | verified |
| M62 | Circadian rhythm sleep–wake disorders, including delayed sleep–wake phase disorder, are formally recognised diagnoses in the international sleep-disorders class | — | verified |
| M63 | Clinical guidelines support strategically timed melatonin in the treatment of delayed sleep–wake phase disorder. | — | verified |
| M64 | Evidence for melatonin in shift-work sleep disorder is weaker and less consistent than for jet lag and delayed sleep–wake phase disorder. | — | verified |
| M65 | The Cochrane shift-work review found melatonin after a night shift gave a mean 24 minutes more daytime sleep (95% CI 9.8–38.9) and 17 minutes more night-time sl | — | verified |
| M66 | The direction and size of melatonin's phase-shifting effect depend on the time it is given relative to the individual's circadian phase, and administration at t | — | verified |
| M67 | The evidence base supporting melatonin for circadian rhythm problems is distinct from, and stronger than, the evidence base for general chronic insomnia. | — | verified |
| M68 | Obstructive sleep apnoea is characterised by repeated upper-airway obstruction during sleep and is diagnosed by a sleep study, not excluded by a person's respon | — | verified |
| M69 | In OSA each event is scored on a sleep study by the fall in airflow with an accompanying drop in blood oxygen and/or a brief arousal, counted per hour (the apno | — | verified |
| M70 | Loud habitual snoring, witnessed breathing pauses or choking/gasping in sleep, and waking unrefreshed after adequate time in bed are recognised indications for | — | verified |
| M71 | Untreated obstructive sleep apnoea is associated with adverse cardiovascular outcomes and impaired daytime function. | — | verified |
| M72 | Chronic insomnia disorder is defined by sleep difficulty occurring at least three nights per week, persisting for at least three months, with associated daytime | — | verified |
| M73 | Restless legs syndrome is a distinct sensorimotor disorder defined by an urge to move the legs that is worse at rest and in the evening and relieved by movement | — | verified |
| M74 | Falling asleep unintentionally during the day, particularly while driving, is a recognised indication for prompt clinical assessment. | — | verified |
| M75 | Acting out dreams or violent movement during sleep is a recognised feature of REM sleep behaviour disorder and warrants clinical assessment. | — | verified |
| M76 | New or worsening sleep problems alongside low mood, anxiety, or a change in medication are a recognised indication for clinical assessment. | — | unsupported → corrected |
| M77 | A child with persistent sleep problems is a recognised indication for clinical assessment rather than a purchase. | — | verified |
| M78 | Sleep problems in someone with significant heart or lung disease, a neuromuscular or neurological condition, or a past stroke are a recognised indication for cl | — | verified |
| M79 | The ACP 2016 guideline recommends cognitive behavioural therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder in adults — a strong | — | verified |
| M80 | The AASM's 2021 behavioural and psychological treatment guideline recommends multicomponent CBT-I for chronic insomnia disorder in adults — a strong recommendat | — | verified |
| M81 | Light is the principal entraining signal for the human circadian system, and appropriately timed light exposure produces measurable circadian phase shifts. | — | verified |
| M82 | A consistent wake/rising time is one of the standard components of multicomponent CBT-I, alongside stimulus control, sleep restriction and cognitive therapy. | — | verified |
| M83 | Sleep-hygiene education delivered as a standalone intervention is not recommended as a treatment for chronic insomnia disorder and performs less well than struc | — | verified |
| M84 | The same guideline bodies that recommend CBT-I as first-line treatment for chronic insomnia did not recommend melatonin for that condition. | — | verified |
| M85 | Access to CBT-I is limited relative to demand, and it is harder for most people to obtain than an over-the-counter supplement. | — | verified |
Ledger exported 2026-07-23. Found something we still got wrong? Tell us — corrections happen in the open. How the books are made: the honest method.